Aerie Pharmaceuticals (NASDAQ:AERI) Earns Buy Rating from Mizuho

Mizuho restated their buy rating on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a report released on Thursday, November 9th. Mizuho currently has a $87.00 target price on the stock.

“We do not view quarterly earnings as an important performance measure of companies like Aerie as valuation is primarily driven by progress of the R&D pipeline.”,” Mizuho’s analyst commented.

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $62.00 target price (up previously from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. Canaccord Genuity reiterated a positive rating and issued a $73.00 target price (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research report on Monday, July 24th. Needham & Company LLC reiterated a buy rating and issued a $76.00 target price (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Finally, Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a hold rating to a strong-buy rating and set a $66.00 target price for the company in a research report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $71.43.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at $61.75 on Thursday. Aerie Pharmaceuticals has a 52 week low of $35.20 and a 52 week high of $66.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24.

Several institutional investors have recently added to or reduced their stakes in AERI. AXA bought a new position in Aerie Pharmaceuticals in the 2nd quarter worth $10,961,000. Goldman Sachs Group Inc. raised its holdings in Aerie Pharmaceuticals by 28.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock worth $10,115,000 after acquiring an additional 49,473 shares during the period. BlackRock Inc. raised its holdings in Aerie Pharmaceuticals by 113,376.8% in the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after acquiring an additional 2,598,596 shares during the period. Boulegeris Investments Inc. raised its holdings in Aerie Pharmaceuticals by 5.2% in the 2nd quarter. Boulegeris Investments Inc. now owns 79,525 shares of the company’s stock worth $4,179,000 after acquiring an additional 3,900 shares during the period. Finally, TIAA CREF Investment Management LLC raised its holdings in Aerie Pharmaceuticals by 8.5% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 124,238 shares of the company’s stock worth $6,529,000 after acquiring an additional 9,781 shares during the period.

TRADEMARK VIOLATION NOTICE: This story was first posted by BBNS and is the property of of BBNS. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/aerie-pharmaceuticals-aeri-buy-rating-reaffirmed-at-mizuho/1771917.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.